Page 12 - Interim Analysis News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos ... BIOPHYTIS SAApril 29, 2021 GMT DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021 PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (...

REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapys 24th Annual Meeting News provided by Share this article Share this article ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Therapys 24 th Annual Meeting taking place from May 11 to 14, 2021, in virtual format. Presentations and posters will be available at https://...

Hits: 143 EMA Confirms Overall Benefit-Risk Profile Remains Positive Company to update the COVID-19 Vaccine Janssen Summary of Product Characteristics and Package Leaflet to include important information on very rare adverse event Johnson & Johnson remains committed to supplying 200 million doses of its COVID-19 vaccine to the European Union, Norway and Iceland NEW BRUNSWICK, NJ, USA I April 20, 2021 I Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines A...

Share this article Share this article NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agencys (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Companys COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combi...

(0) DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection 15.04.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Select...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization March 12, 2021 GMT (PRNewsfoto/Johnson & Johnson) NEW BRUNSWICK, N.J., March 12, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the ...

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavants PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upc...

Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without prior infection after the second dose.Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints. MALVERN, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- O...

Bharat Biotech's vaccine showed 81% efficacy in preventing symptomatic COVID-19 in an interim analysis of a late-stage trial in India, it said on Wednesday, a major boost for the shot shunned by some due to a lack of such data. The positive result also brightens prospects for sales overseas, with the vaccine, India's first successful homemade COVID-19 shot, already attracting interest from more than 40 countries, according to the firm. "COVAXIN demonstrates high clinical efficac...

(0.28) Summary of operational events (more details are provided in the corresponding press releases available on Biophytiss website: www.biophytis.com) Launch of the Phase 2-3 COVA study in patients with severe respiratory manifestation of COVID-19 In May 2020, Biophytis received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP), to proceed with its clinical development program COVA, a two-part study assessing Sarconeos (BIO101) in patients aged 45 and older, ...